Abstract
Oxidative stress-energy depletion therapy using oxidative stress induced by D-amino acid oxidase (DAO) and energy depletion induced by 3-bromopyruvate (3BP) was reported recently (El Sayed et al., Cancer Gene Ther., 19, 1–18, 2012). Even in the presence of oxygen, cancer cells oxidize glucose preferentially to produce lactate (Warburg effect) which seems vital for cancer microenvironment and progression. 3BP is a closely related structure to lactate and pyruvate and may antagonize their effects as a novel mechanism of its action. Pyruvate exerted a potent H2O2 scavenging effect to exogenous H2O2, while lactate had no scavenging effect. 3BP induced H2O2 production. Pyruvate protected against H2O2-induced C6 glioma cell death, 3BP-induced C6 glioma cell death but not against DAO/D-serine-induced cell death, while lactate had no protecting effect. Lactate and pyruvate protected against 3BP-induced C6 glioma cell death and energy depletion which were overcome with higher doses of 3BP. Lactate and pyruvate enhanced migratory power of C6 glioma which was blocked by 3BP. Pyruvate and lactate did not protect against C6 glioma cell death induced by other glycolytic inhibitors e.g. citrate (inhibitor of phosphofructokinase) and sodium fluoride (inhibitor of enolase). Serial doses of 3BP were synergistic with citrate in decreasing viability of C6 glioma cells and spheroids. Glycolysis subjected to double inhibition using 3BP with citrate depleted ATP, clonogenic power and migratory power of C6 glioma cells. 3BP induced a caspase-dependent cell death in C6 glioma. 3BP was powerful in decreasing viability of human glioblastoma multiforme cells (U373MG) and C6 glioma in a dose- and time-dependent manner.
Similar content being viewed by others
References
El Sayed SM, Abou El-Magd RM, Shishido Y, Chung SP, Sakai T, Watanabe H et al (2012) D-amino acid oxidase gene therapy sensitizes glioma cells to the antiglycolytic effect of 3-bromopyruvate. Cancer Gene Therapy 19:1–18
Kawazoe T, Park HK, Iwana S, Tsuge H, Fukui K (2007) Human D-amino acid oxidase: an update and review. Chem Rec 7(5):305–315
Abou El-Magd RM, Park HK, Kawazoe T, Iwana S, Ono K, Chung SP et al (2010a) The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia. J Psychopharmacol 24(7):1055–1067
Abou El-Magd RM, Sasaki C, Kawazoe T, El Sayed SM, Yorita K, Shishido Y et al (2010b) Bioprocess development of the production of the mutant P-219-L human D-amino acid oxidase for high soluble fraction expression in recombinant Escherichia coli. Biochem Eng J 52(2–3):236–247
Zorzano A, Fandos C, Palacín M (2000) Role of plasma membrane transporters in muscle metabolism. Biochem J 349:667–688
Warburg O (1956) On the origin of cancer cells. Science 123(3191):309–314
Végran F, Boidot R, Michiels C, Sonveaux P, Feron O (2011) Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Res 71(7):2550–2560
Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, et al. (2011) Increased survival of glioblastoma patients who respond to anti-angiogenic therapy with elevated blood perfusion. Cancer Research
Mac M, Nałecz KA (2003) Expression of monocarboxylic acid transporters (MCT) in brain cells. Implication for branched chain alpha-ketoacids transport in neurons. Neurochem Int 43(5):305–309
Grobben B, De Deyn PP, Slegers H (2002) Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell and Tissue Research 310(3):257–270
Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M et al (2007) Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109(9):3812–3819
Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW et al (2001) Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 51(2):349–3453
Yabu M, Shime H, Hara H, Saito T, Matsumoto M, Seya T et al (2011) IL-23-dependent and -independent enhancement pathways of IL-17A production by lactic acid. Int Immunol 23(1):29–41
Walenta S, Schroeder T, Mueller-Klieser W (2004) Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chem 11(16):2195–2204
Gatenby RA, Gawlinski ET (2003) The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res 63(14):3847–3854
Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ (2006) Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 66(10):5216–5223
Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25(34):4777–4786
Fantin VR, St-Pierre J, Leder P (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9(6):425–434
Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA et al (1997) c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A 94(13):6658–6663
Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O et al (2006) p53 regulates mitochondrial respiration. Science 312(5780):1650–1653
Desagher S, Glowinski J, Prémont J (1997) Pyruvate protects neurons against hydrogen peroxide-induced toxicity. J Neurosci 17(23):9060–9067
Marín-Hernández A, Rodríguez-Enríquez S, Vital-González PA, Flores-Rodríguez FL, Macías-Silva M, Sosa-Garrocho M et al (2006) Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase. FEBS J 273(9):1975–1988
Zhang X, Varin E, Allouche S, Lu Y, Poulain L, Icard P (2009) Effect of citrate on malignant pleural mesothelioma cells: a synergistic effect with cisplatin. Anticancer Res 29(4):1249–1254
Halabe Bucay A (2009) Hypothesis proved…citric acid (citrate) does improve cancer: a case of a patient suffering from medullary thyroid cancer. Medical Hypotheses 73(2):271
Lu Y, Zhang X, Zhang H, Lan J, Huang G, Varin E et al (2011) Citrate induces apoptotic cell death: a promising way to treat gastric carcinoma? Anticancer Res 31(3):797–805
Nagoba BS, Punpale AS, Ayachit R, Gandhi RC, Wadher BJ (2011) Citric acid treatment of postoperative wound in an operated case of synovial sarcoma of the knee. Int Wound J 8(4):425–427
Yousefi S, Owens JW, Cesario TC (2004) Citrate shows specific, dose-dependent lympholytic activity in neoplastic cell lines. Leukemia & Lymphoma 45(8):1657–1665
Park HK, Shishido Y, Ichise-Shishido S, Kawazoe T, Ono K, Iwana S et al (2006) Potential role for astroglial D-amino acid oxidase in extracellular D-serine metabolism and cytotoxicity. J Biochem 139(2):295–304
Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA (2009) Spheroid-based drug screen: considerations and practical approach. Nat Protoc 4(3):309–324
Shankardas J, Patil RV, Vishwanatha JK (2010) Effect of down-regulation of aquaporins in human corneal endothelial and epithelial cell lines. Mol Vis 16:1538–1548
Aykin-Burns N, Ahmad IM, Zhu Y, Oberley LW, Spitz DR (2009) Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J 418(1):29–37
Chung SP, Sogabe K, Park HK, Song Y, Ono K, Abou El-Magd RM et al (2010) Potential cytotoxic effect of hydroxypyruvate produced from D-serine by astroglial D-amino acid oxidase. J Biochem 148(6):743–753
Robert K, Murray Daryl K, Granner Peter A, Mayes and Victor Rodwell W (2003) Harper’s illustrated biochemistry. (26th edition), Overview of Metabolism (pp. 122–127). Lange Medical Books/McGraw-Hill Medical Publishing Division
Ko YH, Pedersen PL, Geschwind JF (2001) Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173(1):83–91
Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I et al (2009) Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res 12:4909–4918
Nakano A, Tsuji D, Miki H, Cui Q, El Sayed SM, Ikegame A, et al. (2011) Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells. PLoS One, 6(11)
Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, Yu Q (2008) Merlin is a potent inhibitor of glioma growth. Cancer Res 68(14):5733–5742
Mohri M, Nitta H, Yamashita J (2000) Expression of multidrug resistance-associated protein (MRP) in human gliomas. Journal of Neurooncology 49(2):105–115
Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN et al (2005) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65(2):613–621
Baierlein JL, Foster JM (1968) Studies on the energy metabolism of human leukocytes II Mechanism of the Pasteur effect in human leukocytes. Blood 32(3):412–422
Krug AW, Völker K, Dantzler WH, Silbernagl S (2007) Why is D-serine nephrotoxic and alpha-aminoisobutyric acid protective? American Journal of Physiology: Renal Physiology 293(1):382–390
Orozco-Ibarra M, Medina-Campos ON, Sánchez-González DJ, Martínez-Martínez CM, Floriano-Sánchez E, Santamaría A et al (2007) Evaluation of oxidative stress in D-serine induced nephrotoxicity. Toxicology 229(1–2):123–35
Marí M, Bai J, Cederbaum AI (2002) Toxicity by pyruvate in HepG2 cells depleted of glutathione: role of mitochondria. Free Radic Biol Med 32(1):73–83
Pereira da silva AP, El-Bacha T, Kyaw N, dos Santos RS, da Silva WS, Almeida FC et al (2009) Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J 417(3):717–726
Stanbrook HS, McMurtry IF (1983) Inhibition of glycolysis potentiates hypoxic vasoconstriction in rat lungs. J Appl Physiol 55(5):1467–1473
Pedersen PL (2007) The cancer cell’s “power plants” as promising therapeutic targets: an overview. J Bioenerg Biomembr 39(1):1–12
Nemeria N, Volkov A, Brown A, Yi J, Zipper L, Guest JR et al (1998) Systematic study of the six cysteines of the E1 subunit of the pyruvate dehydrogenase multienzyme complex from Escherichia coli: none is essential for activity. Biochemistry 37(3):911–922
Korotchkina LG, Showkat, Ali M, Patel MS (1999) Involvement of alpha-cysteine-62 and beta-tryptophan-135 in human pyruvate dehydrogenase catalysis. Arch Biochem Biophys 369(2):277–287
Rícný J, Tucek S (1981) Acetyl coenzyme A and acetylcholine in slices of rat caudate nuclei incubated in the presence of metabolic inhibitors. J Biol Chem 256(10):4919–4923
Mulet C, Lederer F (1977) Bromopyruvate as an affinity label for baker’s yeast flavocytochrome b2. Kinetic study of the inactivation reaction. Eur J Biochem 73(2):443–447
Thangaraju M, Karunakaran SK, Itagaki S, Gopal E, Elangovan S, Prasad PD et al (2009) Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate. Cancer 115(20):4655–4666
Halestrap AP, Price NT (1999) The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 343(2):281–299
De Bruijne AW, Vreeburg H, Van Steveninck J (1983) Kinetic analysis of L-lactate transport in human erythrocytes via the monocarboxylate-specific carrier system. Biochim Biophys Acta 732(3):562–568
Garcia CK, Goldstein JL, Pathak RK, Anderson RG, Brown MS (1994) Molecular characterization of a membrane transporter for lactate, pyruvate, and other monocarboxylates: implications for the Cori cycle. Cell 76(5):865–873
McCullagh KJ, Poole RC, Halestrap AP, O’Brien M, Bonen A (1996) Role of the lactate transporter (MCT1) in skeletal muscles. Am J Physiol 271(1):143–150
Semenza GL (2008) Tumor metabolism: cancer cells give and take lactate. J Clin Investig 118(12):3835–3837
Colen CB, Shen Y, Ghoddoussi F, Yu P, Francis TB, Koch BJ et al (2011) Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia 13(7):620–632
Mathupala SP, Colen CB, Parajuli P, Sloan AE (2007) Lactate and malignant tumors: a therapeutic target at the end stage of glycolysis. J Bioenerg Biomembr 39(1):73–77
Stubbs M, McSheehy PM, Griffiths JR, Bashford CL (2000) Causes and consequences of tumour acidity and implications for treatment. Molecular Medicine Today 6(1):15–19
Suh SY, Ahn HY (2007) Lactate dehydrogenase as a prognostic factor for survival time of terminally ill cancer patients: a preliminary study. Eur J Cancer 43(6):1051–1059
Dell’Antone P (2009) Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent. Medicinal Chemistry 5(6):491–496
Lang VJ, Leystra-Lantz C, Cook RA (1987) Characterization of the specific pyruvate transport system in Escherichia coli K-12. J Bacteriol 169(1):380–385
Babu E, Ramachandran S, CoothanKandaswamy V, Elangovan S, Prasad PD, Ganapathy V et al (2011) Role of SLC5A8, a plasma membrane transporter and a tumor suppressor in the antitumor activity of dichloroacetate. Oncogene 30(38):4026–4037
Raghunand N, Gatenby RA, Gillies RJ (2003) Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 76(1):11–22
Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS et al (2004) Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochemical and Biophysical Research Communications 324(1):269–275
Kobryn CE, Fiskum G (1992) Differential sensitivity of AS-30D rat hepatoma cells and normal hepatocytes to anoxic cell damage. Am J Physiol 262(6):1384–1387
Goetze K, Walenta S, Ksiazkiewicz M, Kunz-Schughart LA, Mueller-Klieser W (2011) Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int J Oncol 39(2):453–463
Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK, et al. (2000) High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Research, 15, 60(4): 916–921
Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJ et al (2009) Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 113(9):2014–2021
Ihrlund LS, Hernlund E, Khan O, Shoshan MC (2008) 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Molecular Oncology 2(1):94–101
Dean M (2009) ABC transporters, drug resistance, and cancer stem cells. Journal of Mammary Gland Biology and Neoplasia 14(1):3–9
Zhou Y, Tozzi F, Chen J, Fan F, Xia L, Wang J, et al. (2011) Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Research
Akers LJ, Fang W, Levy AG, Franklin AR, Huang P, Zweidler-McKay PA (2011) Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin. Leuk Res 35(6):814–820
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
El Sayed, S.M., El-Magd, R.M.A., Shishido, Y. et al. 3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects. J Bioenerg Biomembr 44, 61–79 (2012). https://doi.org/10.1007/s10863-012-9409-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10863-012-9409-4